1044589-96-9

Upstream product

• 69339-86-2 1,2,3,5-tetra-O-benzoyl-α-D-ribofuranoside 
• 22224-41-5 1,3,5-tri-O-benzoyl-α-D-ribofuranoside 
• 157037-56-4 1,3,5-tri-O-benzoyl-2-oxo-α-D-erythro-pentofuranose 
• 4301-14-8 acetylenemagnesium bromide 

Downstream Products

• 1044589-97-0 (2R,3R,4R,5S)-4-benzoyloxy-5-benzoyloxymethyl-3-ethynyl-tetrahydrofuran-2,3-diol 
• 1443997-55-4 (2R,3R,4R,5R)-5-((benzoyloxy)methyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-ethynyltetrahydrofuran-3,4-diyldibenzoate 
• 1443997-54-3 (2R,3R,4R,5R)-5-((benzoyloxy)methyl)-3-ethynyltetrahydrofuran-2,3,4-triyl tribenzoate 
• 1207542-76-4 (2R,3R,4R,5R)-4-benzoyloxy-5-benzoyloxymethyl-3-ethynyl-tetrahydrofuran-2,3-diol 

Relevant academic research and scientific papers

Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase

To identify a potent and selective nucleoside inhibitor of dengue virus RNA-dependent RNA polymerase, a series of 2′- and/or 4′-ribose sugar modified uridine nucleoside phosphoramidate prodrugs and their corresponding triphosphates were synthesized and evaluated. Replacement of 2′-OH with 2′-F led to be a poor substrate for both dengue virus and human mitochondrial RNA polymerases. Instead of 2′-fluorination, the introduction of fluorine at the ribose 4′-position was found not to affect the inhibition of the dengue virus polymerase with a reduction in uptake by mitochondrial RNA polymerase. 2′-C-ethynyl-4′-F-uridine phosphoramidate prodrug displayed potent anti-dengue virus activity in the primary human peripheral blood mononuclear cell-based assay with no significant cytotoxicity in human hepatocellular liver carcinoma cell lines and no mitochondrial toxicity in the cell-based assay using human prostate cancer cell lines.

ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E

The present disclosure is directed toward alkynyl nucleoside analogs, compositions comprising these compounds, and their use for treating hepatitis E infections.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Picornaviridae and/or Flaviviridae viral infections with one or more nucleotide analogs.

NEW ANTIVIRAL MODIFIED NUCLEOSIDES

This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.

NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS

This invention relates to novel nucleoside compounds of formula (I) that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.